Orthocell (ASX:OCC) was granted a medical device license by Health Canada to start sales of its nerve repair collagen wrap Remplir in the country, according to a Wednesday Australian bourse filing.
The firm noted that the approval was granted earlier than expected after it lodged an application in February.
The company is currently in talks to appoint non-exclusive local specialist distribution partners in Canada to drive market penetration, and the first sales are expected in the second half, the filing said.
Orthocell's shares surged past 13% in recent trading on Wednesday.